U.S. Markets close in 1 hr 50 mins
  • S&P 500

    4,398.75
    -20.40 (-0.46%)
     
  • Dow 30

    34,941.63
    -142.90 (-0.41%)
     
  • Nasdaq

    14,683.85
    -94.41 (-0.64%)
     
  • Russell 2000

    2,226.81
    -13.22 (-0.59%)
     
  • Crude Oil

    74.16
    +0.54 (+0.73%)
     
  • Gold

    1,817.70
    -18.10 (-0.99%)
     
  • Silver

    25.53
    -0.25 (-0.96%)
     
  • EUR/USD

    1.1864
    -0.0032 (-0.2729%)
     
  • 10-Yr Bond

    1.2320
    -0.0370 (-2.92%)
     
  • Vix

    17.95
    +0.25 (+1.41%)
     
  • GBP/USD

    1.3895
    -0.0062 (-0.4474%)
     
  • USD/JPY

    109.7960
    +0.3350 (+0.3060%)
     
  • BTC-USD

    38,996.04
    -689.34 (-1.74%)
     
  • CMC Crypto 200

    925.52
    -24.38 (-2.57%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

·2 min read

BEND, Ore., July 22, 2021 (GLOBE NEWSWIRE) --

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)

Stonepine Capital, L.P.

Company dealt in

Strongbridge Biopharma plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

Ordinary Shares

Date of dealing

Purchase - 21/07/2021

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

4,091,221

6.037%

0

(2) Derivatives (other than options)

0

0

(3) Options and agreements to purchase/sell

0

0

Total

4,092,221

6.037%

0

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

N/A

N/A

(2) Derivatives (other than options)

N/A

N/A

(3) Options and agreements to purchase/sell

N/A

N/A

Total

N/A

N/A

Ap20

1. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

Purchase

167,693

$ 2.7436

(b) Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name,
e.g. call option

Writing, selling,
purchasing,
varying etc.

Number of securities
to which the option
relates (Note 7)

Exercise
price

Type, e.g.
American,
European etc.

Expiry
date

Option money
paid/received
per unit (Note 5)

(ii) Exercising

Product name,
e.g. call option

Number of securities

Exercise price per
unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction
(Note 8)

Details

Price per unit
(if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

Is a Supplemental Form 8 attached? (Note 9)

NO


Date of disclosure

22 July 2021

Contact name

Jeff Nunnenkamp

Telephone number

+1 541-647-5673

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A